The National Research Council Canada has researched and developed peptides with new anti-angiogenic properties which have proven to be very effective in deterring different stimulations of angiogenesis. Angiogenesis is vital for the growth as well as the progression of malignant tissues and tumours. It is what medics normally use to determine the extent of malignancy in the body.
Research has shown that by restricting blood supply to the tumours by preventing angiogenesis, the growth of tumours as well as metastasis can be controlled. The current anti-angiogenic drugs available today are being used to target specific stimulators, though they are not sufficient to reduce significantly the tumour burden and help in prolonging life.
The peptides developed by the National Research Council Canada exhibits direct anti-tumoregenic properties for different types of tumors and these findings have been validated in living organisms. The activity of the anti-angiogenic against multiple stimulators and combined with the direct inhibition for the growth of tumors has presented peptides as a promising and a viable treatment against cancer and other malignant tumours.
How anti-angiogenic agents work
The anti-angogenic peptides developed by the National Research Council Canada work by inhibiting the angiogenic responses brought about by different kinds of growth hormones. The peptides also stop the direct anti-tumoregenic properties against different tumour types. The Council has demonstrated that the anti-tumoregenic and anti-angiogenic activities of the peptides are found at the C-terminal sequences of the proteins and is partly assisted by the prevention of the activities of intracellular cathepsin L and B in the tumour cells.
The council has also discovered that the anti-angiogenic agents have a number of advantages over the conventional anti-cancer treatments. For example, they have a direct access from the circulation and they also exhibit low rate of drug resistance because of the genetic stability the tumoral cells. While preclinic tests of these agents have shown promising results with complete or partial regression of the tumour cells without any resistance to the drugs, studies have only revealed the stabilization of the tumors with very little to no regression.